Free Trial
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics logo
$13.25 +0.08 (+0.61%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$13.25 0.00 (0.00%)
As of 08/7/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Stoke Therapeutics Stock (NASDAQ:STOK)

Key Stats

Today's Range
$12.86
$13.27
50-Day Range
$9.61
$14.27
52-Week Range
$5.35
$16.15
Volume
418,198 shs
Average Volume
784,097 shs
Market Capitalization
$723.45 million
P/E Ratio
16.77
Dividend Yield
N/A
Price Target
$25.80
Consensus Rating
Buy

Company Overview

Stoke Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

STOK MarketRank™: 

Stoke Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 207th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Stoke Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Stoke Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stoke Therapeutics is 16.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stoke Therapeutics is 16.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.85.

  • Price to Book Value per Share Ratio

    Stoke Therapeutics has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    21.06% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 0.26%, indicating that investor sentiment is improving.
  • Dividend Yield

    Stoke Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Stoke Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.06% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 0.26%, indicating that investor sentiment is improving.
  • News Sentiment

    Stoke Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    11 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $140,095.00 in company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Stoke Therapeutics is held by insiders.

  • Read more about Stoke Therapeutics' insider trading history.
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
See More Headlines

STOK Stock Analysis - Frequently Asked Questions

Stoke Therapeutics' stock was trading at $11.03 on January 1st, 2025. Since then, STOK shares have increased by 20.1% and is now trading at $13.25.

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, March, 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company earned $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a trailing twelve-month return on equity of 19.08% and a net margin of 26.33%.

Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional shareholders of Stoke Therapeutics include Skorpios Trust (5.96%), Assenagon Asset Management S.A. (0.99%), Aviva PLC (0.08%) and Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Jonathan Allan, Stephen J Tulipano and Barry Ticho.
View institutional ownership trends
.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

Last Earnings
3/24/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STOK
CIK
1623526
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$35.00
Low Price Target
$18.00
Potential Upside/Downside
+94.7%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.79
Trailing P/E Ratio
16.77
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.98 million
Net Margins
26.33%
Pretax Margin
27.00%
Return on Equity
19.08%
Return on Assets
15.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.41
Quick Ratio
8.41

Sales & Book Value

Annual Sales
$190.91 million
Price / Sales
3.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.32 per share
Price / Book
3.07

Miscellaneous

Outstanding Shares
54,597,000
Free Float
49,410,000
Market Cap
$723.41 million
Optionable
Optionable
Beta
1.15

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:STOK) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners